An interventional study of Dosing Guidance System to be used with both time and amount of insulin as input and Dosing Guidance System to be used with only time of insulin as input in Type 1 Diabetes and Type 2 Diabetes, sponsored by Rabin Medical Center. Recruiting at 2 sites in 2 countries. Open to participants aged 6 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-11.
Sponsored by Rabin Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center — 8 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Rabin Medical Center.
Among the 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center, this one is the 14th largest by planned enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2025, is one of 31 with no phase, and was the 41st registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →8 of the 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center are open now, in 2 countries. Recruiting first, the newest first:
Rabin Medical Center · Sites in Israel
Ages 2–45 · Healthy volunteers
Rabin Medical Center · Sites in Israel
Ages 6–18
Rabin Medical Center · Sites in Israel
Ages 18–35
Rabin Medical Center · Sites in Israel
Ages 2–45 · Healthy volunteers
Rabin Medical Center · Sites in Israel
Ages 9 mo–5 yrs
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 6 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 30 across the 38 interventional studies, 10,150 across the 4 observational. Of the 31 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Rabin Medical Center is the lead sponsor of 393 studies on the registry; 30 are open to participants now.
2 of the studies in Diabetes Mellitus, Type 1 by Rabin Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04834518Rabin Medical CenterScreening for Islet Autoantibodies in the Israeli Paediatric General Population for Detection of Pre-symptomatic Type-1 Diabetes Mellitus | 2027-03-31 |
| NCT06687434Rabin Medical CenterCarb Counting vs. Simplified Qualitative Meal-Size Estimation | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A prospective, randomized, single blind, two-arms, multicenter study. The study aims to assess the safety of a dosing-guided system (DGS) that provides direct advice on insulin dosing recommendations and diabetes management to individuals with diabetes using insulin or starting basal insulin therapy, guided by their continuous glucose monitoring (CGM).
The study population will include up to 45 individuals with diabetes, distributed as follows: 15 with Type 1 diabetes (T1D) and 15 with Type 2 diabetes (T2D), both on MDI therapy and 15 with T2D using or starting to use basal insulin.
The study will include a 2- to 4-week run-in period followed by a 6-week intervention period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Segment 1: Using basal-bolus MDI therapy, i.e. basal insulin and a bolus that is either:
Participants using the following type of insulin as directed in the instructions for use:
Exclusion Criteria:
Relevant severe organ disorders (diabetic nephropathy, diabetic retinopathy, diabetic foot syndrome) or any secondary disease or complication of diabetes mellitus, such as:
Individuals who are using one of the following types of insulin:
i. Premix NPH/ Regular (e.g. Humalin 70/30, Novolog 70/30) ii. Premix analogs (e.g, Novolog mix 70/30, Hu,alog mix 75, 25, Humalog Mix 50/50) c. Inhale insulin (e.g. Afrezza)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Any insulin dosing event manually logged by the participant, the DGS will receive the time and amount of the dose as input.
Device: Dosing Guidance System to be used with both time and amount of insulin as input
Any insulin dosing event manually logged by the participant, the DGS will receive only the time of the dose as input
Device: Dosing Guidance System to be used with only time of insulin as input
Any insulin dosing event manually logged by the participant, the DGS will receive the time and amount of the dose as input
Also known as: endo.digital (Modi algorithm)
any insulin dosing event manually logged by the participant, the DGS will receive only the time of the dose as input
Also known as: endo.digital (Modi algorithm)
Sensor glucose percentage of time in hypoglycemia below 54 mg/dL
Will be compared between the last two weeks of the run-in period and the last two weeks of the intervention
Time frame: Aafter 6 weeks of intervention period
Number of events of glucose readings below 54 mg/dL
An event is defined as a period of at least 15 minutes of glucose readings below 54 mg/dL. Will be compared between the last two weeks of the run-in period and the last two weeks of the intervention
Time frame: After 6 weeks of intervention period
Sensor glucose percentage of time in hyperglycemia above 250 mg/dL
Will be compared between the last two weeks of the run-in period and the last two weeks of the intervention
Time frame: After 6 weeks of intervention period
Glucose Management Indicator (GMI)
Time frame: After 6 weeks of intervention period
Percentage of glucose readings between 70- 180 mg/dl
Will be compared between the last two weeks of the run-in period and the last two weeks of the intervention
Time frame: After 6 weeks of intervention period
Change in (Hemoglobin A1c) HbA1C post-study treatment
Time frame: After 6 weeks of intervention period
Percentage of glucose readings below 70 mg/dl
Will be compared between the last two weeks of the run-in period and the last two weeks of the intervention
Time frame: After 6 weeks of intervention period
Mean sensor glucose
Will be compared between the last two weeks of the run-in period and the last two weeks of the intervention
Time frame: After 6 weeks of intervention period
Glucose variability measured by Standard Deviation (SD) and CV%
Will be compared between the last two weeks of the run-in period and the last two weeks of the intervention
Time frame: After 6 weeks of intervention period
Time to reach optimal insulin dose
Time frame: After 6 weeks of intervention period
Total insulin dose and the amount of basal and/or bolus insulin dose
Time frame: After 6 weeks of intervention period
Device satisfaction questioner
Time frame: After 6 weeks of intervention period
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for May 2025; primary completion for May 2026, 12 months later.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 12 months is below that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.